Cargando…

ONC201 and imipridones: Anti-cancer compounds with clinical efficacy

ONC201 was originally discovered as TNF-Related Apoptosis Inducing Ligand (TRAIL)-inducing compound TIC10. ONC201 appears to act as a selective antagonist of the G protein coupled receptor (GPCR) dopamine receptor D2 (DRD2), and as an allosteric agonist of mitochondrial protease caseinolytic proteas...

Descripción completa

Detalles Bibliográficos
Autores principales:	Prabhu, Varun Vijay, Morrow, Sara, Rahman Kawakibi, Abed, Zhou, Lanlan, Ralff, Marie, Ray, Jocelyn, Jhaveri, Aakash, Ferrarini, Isacco, Lee, Young, Parker, Cassandra, Zhang, Yiqun, Borsuk, Robyn, Chang, Wen-I, Honeyman, Joshua N., Tavora, Fabio, Carneiro, Benedito, Raufi, Alexander, Huntington, Kelsey, Carlsen, Lindsey, Louie, Anna, Safran, Howard, Seyhan, Attila A., Tarapore, Rohinton S., Schalop, Lee, Stogniew, Martin, Allen, Joshua E., Oster, Wolfgang, El-Deiry, Wafik S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2020
Materias:	Review article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7588802/ https://www.ncbi.nlm.nih.gov/pubmed/33142238 http://dx.doi.org/10.1016/j.neo.2020.09.005

Ejemplares similares

Discovery and clinical introduction of first-in-class imipridone ONC201
por: Allen, Joshua E., et al.
Publicado: (2016)

Correction: Discovery and clinical introduction of first-in-class imipridone ONC201
por: Allen, Joshua E., et al.
Publicado: (2021)

Cancer stem cell-related gene expression as a potential biomarker of response for first-in-class imipridone ONC201 in solid tumors
por: Prabhu, Varun V., et al.
Publicado: (2017)

Combination of ONC201 and TLY012 induces selective, synergistic apoptosis in vitro and significantly delays PDAC xenograft growth in vivo
por: Jhaveri, Aakash V., et al.
Publicado: (2021)

DIPG-62. PRECLINICAL EVALUATION OF IMIPRIDONE-BASED COMBINATION THERAPIES IN PEDIATRIC H3K27M MUTANT DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)
por: Borsuk, Robyn, et al.
Publicado: (2020)

Antitumorigenic effect of combination treatment with ONC201 and TRAIL in endometrial cancer in vitro and in vivo
por: Ray, Jocelyn E., et al.
Publicado: (2021)

Role of Dopamine Receptors in the Anticancer Activity of ONC201()()
por: Kline, Christina Leah B., et al.
Publicado: (2017)

TRAIL receptor agonists convert the response of breast cancer cells to ONC201 from anti-proliferative to apoptotic
por: Ralff, Marie D., et al.
Publicado: (2020)

EZH2i EPZ-6438 and HDACi vorinostat synergize with ONC201/TIC10 to activate integrated stress response, DR5, reduce H3K27 methylation, ClpX and promote apoptosis of multiple tumor types including DIPG
por: Zhang, Yiqun, et al.
Publicado: (2021)

HGG-42. PEDIATRIC H3K27M MUTANT DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) SHOWS ROBUST RESPONSE TO IMIPRIDONE BASED COMBINATION THERAPY
por: Borsuk, Robyn, et al.
Publicado: (2021)

A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma
por: Arrillaga-Romany, Isabel, et al.
Publicado: (2017)

The Imipridone ONC201 Induces Apoptosis and Overcomes Chemotherapy Resistance by Up-Regulation of Bim in Multiple Myeloma
por: Tu, Yong-sheng, et al.
Publicado: (2017)

Targeting Dopamine Receptor D2 by Imipridone Suppresses Uterine Serous Cancer Malignant Phenotype
por: Hu, Wen, et al.
Publicado: (2020)

DIPG-57. TRANSCRIPTOMIC AND PROTEOMIC ANALYSES OF DIPG RESPONSE TO ONC201
por: Sridharan, Sreepradha, et al.
Publicado: (2020)

ONC201 selectively induces apoptosis in cutaneous T-cell lymphoma cells via activating pro-apoptotic integrated stress response and inactivating JAK/STAT and NF-κB pathways
por: Ni, Xiao, et al.
Publicado: (2017)

ONC212 is a Novel Mitocan Acting Synergistically with Glycolysis Inhibition in Pancreatic Cancer
por: Ferrarini, Isacco, et al.
Publicado: (2021)

DIPG-80. CLINICAL AND RADIOGRAPHIC RESPONSE TO ONC201 IN A PEDIATRIC PATIENT WITH A THALAMIC H3K27M AND BRAFV600E MUTANT DIFFUSE MIDLINE HIGH GRADE GLIOMA
por: Duke, Elizabeth, et al.
Publicado: (2020)

First-In-Class Small Molecule ONC201 Induces DR5 and Cell Death in Tumor but Not Normal Cells to Provide a Wide Therapeutic Index as an Anti-Cancer Agent
por: Allen, Joshua E., et al.
Publicado: (2015)

Correction: First-In-Class Small Molecule ONC201 Induces DR5 and Cell Death in Tumor but Not Normal Cells to Provide a Wide Therapeutic Index as an Anti-Cancer Agent
por: Allen, Joshua E., et al.
Publicado: (2016)

Advances in Liquid Biopsy Technology and Implications for Pancreatic Cancer
por: Raufi, Alexander G., et al.
Publicado: (2023)

Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration
por: Stein, Mark N., et al.
Publicado: (2019)

Imipridone family on successful TRAIL
por: Anderson, Peter M., et al.
Publicado: (2017)

DIPG-52. PHASE I CLINICAL TRIAL OF ONC201 IN PEDIATRIC H3 K27M-MUTANT GLIOMA OR NEWLY DIAGNOSED DIPG
por: Gardner, Sharon, et al.
Publicado: (2020)

Correction: Hu, W., et al. Targeting Dopamine Receptor D2 by Imipridone Suppresses Uterine Serous Cancer Malignant Phenotype. Cancers 2020, 12, 2436
por: Hu, Wen, et al.
Publicado: (2021)

HGG-15. THE IMIPRIDONE ONC201 IN COMBINATION WITH THE ONCOLYTIC ADENOVIRUS DELTA-24-RGD HAS A SYNERGISTIC EFFECT IN PRECLINICAL MODELS OF PHGGS AND DMGS
por: de la Nava, Daniel, et al.
Publicado: (2021)

Commentary: GSK-3 Inhibition as a Therapeutic Approach Against SARs CoV2: Dual Benefit of Inhibiting Viral Replication While Potentiating the Immune Response
por: De Souza, Andre, et al.
Publicado: (2020)

Imipridone ONC212 activates orphan G protein-coupled receptor GPR132 and integrated stress response in acute myeloid leukemia
por: Nii, Takenobu, et al.
Publicado: (2019)

SYST-07 WINDOW-OF-OPPORTUNITY STUDY OF ONC201 IN PEDIATRIC PATIENTS WITH DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) AND THALAMIC GLIOMA
por: Odia, Yazmin, et al.
Publicado: (2022)

A Novel Therapeutic Mechanism of Imipridones ONC201/ONC206 in MYCN-Amplified Neuroblastoma Cells via Differential Expression of Tumorigenic Proteins
por: El-Soussi, Sarra, et al.
Publicado: (2021)

Phase II Study of ONC201 in Neuroendocrine Tumors including Pheochromocytoma-Paraganglioma and Desmoplastic Small Round Cell Tumor
por: Anderson, Peter M., et al.
Publicado: (2022)

MODL-06. PRECLINICAL EFFICACY OF THE IMIPRIDONE ONC-206 AGAINST MEDULLOBLASTOMA
por: Malhotra, Anshu, et al.
Publicado: (2020)

The angular structure of ONC201, a TRAIL pathway-inducing compound, determines its potent anti-cancer activity
por: Wagner, Jessica, et al.
Publicado: (2015)

Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway
por: Allen, Joshua E, et al.
Publicado: (2015)

Strategies to sensitize cancer cells to immunotherapy
por: George, Andrew, et al.
Publicado: (2021)

Molecular Targets for Novel Therapeutics in Pediatric Fusion-Positive Non-CNS Solid Tumors
por: Chang, Wen-I, et al.
Publicado: (2022)

Modulating the unfolded protein response with ONC201 to impact on radiation response in prostate cancer cells
por: Amoroso, Francesca, et al.
Publicado: (2021)

Phase I dose escalation and expansion trial of single agent ONC201 in pediatric diffuse midline gliomas following radiotherapy
por: Gardner, Sharon L, et al.
Publicado: (2022)

Anti-pancreatic cancer activity of ONC212 involves the unfolded protein response (UPR) and is reduced by IGF1-R and GRP78/BIP
por: Lev, Avital, et al.
Publicado: (2017)

Anti-tumor effects of ONC201 in combination with VEGF-inhibitors significantly impacts colorectal cancer growth and survival in vivo through complementary non-overlapping mechanisms
por: Wagner, Jessica, et al.
Publicado: (2018)

HGG-18. CLINICAL EFFICACY OF ONC201 IN THALAMIC H3 K27M-MUTANT GLIOMA
por: Kawakibi, Abed Rahman, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_co5j2v8rkj105qctunfegff47n